Abstract
Meningiomas are the most common primary tumor in the central nervous system, yet an effective systemic treatment remains a challenge. We present a grade 2 meningioma that resulted in a positive and prolonged response to pembrolizumab. Our case had polybromo-1 (PBRM1) and BAP1 functional loss, tumor mutational burden of 4 Muts/Mb, stable microsatellite status, and a PD-L1 tumor proportion score of <1%. We add to the limited literature regarding PBRM1 mutations in meningiomas. We discuss our findings in relation to the ongoing investigation of immune checkpoint inhibitor therapy in treating higher-grade refractory meningiomas.
| Original language | English |
|---|---|
| Article number | 1587752 |
| Journal | Frontiers in Oncology |
| Volume | 15 |
| DOIs | |
| State | Published - 2025 |
Bibliographical note
Publisher Copyright:Copyright © 2025 Reusch, Peh, Morgan, Momo, Orren, Rock, Pittman, Neltner, Kolesar and Villano.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. The Research Communications Office of the University of Kentucky Markey Cancer Center (P30CA177558) supported the publication of the manuscript but did not contribute to the writing of the manuscript.
| Funders | Funder number |
|---|---|
| University of Kentucky Markey Comprehensive Cancer Center | P30CA177558 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- PBRM1
- PD-1/L1
- atypical meningioma
- grade 2 meningioma
- immunotherapy
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver